viewElixinol Global Ltd

Elixinol Global buoyed by United Nations reclassification of cannabis as less dangerous drug

This UN decision, which acknowledges medicinal usefulness of cannabis and clarifies that CBD is not under international drug control, is expected to have a substantial impact on Elixinol’s ability to drive product sales in Europe and other countries influenced by UN decision-making.

Elixinol Global Ltd - Elixinol Global to benefit from UN’s decision to reclassify cannabis as less dangerous drug
This decision is another signal towards global regulatory relaxation of CBD legislation

Elixinol Global Ltd (ASX:EXL) (OTCMKTS:ELLXF) (FRA:E8M) is encouraged by a United Nations decision to remove cannabis and its derivatives from schedule IV of the 1961 Single Convention on Narcotic Drugs following recommendations from the World Health Organisation (WHO).

This emanated from WHO recommendation 5.1, which recognises the medical value of cannabis and will see it removed from Schedule IV of the 1961 Convention - reserved for substances with ‘particularly dangerous properties’ and little or no therapeutic value.

UN adoption of the WHO recommendations acknowledges the medicinal usefulness of cannabis and clarifies that cannabidiol (CBD) is not under international control.

Independent assessment

This vote followed an independent scientific assessment undertaken by leading experts, convened by WHO in 2017-2018, where evidence and testimonials from all corners of the world were reviewed.

It also follows last week’s landmark ruling from the European Union's highest court, the Court of Justice of the European Union (CJEU) that CBD is not a narcotic as it does not appear to have any psychotropic effect or any harmful effect on human health.

“Possibly most important day since 1961”

Elixinol chief executive officer Oliver Horn said: “This is possibly the most important day for cannabidiol, or CBD, since it was scheduled as a narcotic in 1961.

“Since that time, substantial resources have been deployed into understanding CBD and while we have long understood its significant therapeutic value, international scheduling has held it back.

"This UN vote recognises CBD’s potential, which we believe will positively impact Elixinol’s ability to conduct business in our key regions.

“Over the last two years, we’ve already built a substantial base in Europe which has contributed significantly to our recent performance and from which we can now unlock new value.

“Given the significant influence of the UN, we also expect positive follow-on effects into other countries where we operate.”

Shares higher

There was a strong response from investors to the news with shares more than 43% higher to A$0.265.

Quick facts: Elixinol Global Ltd

Price: 0.19 AUD

Market: ASX
Market Cap: $59.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Elixinol Global Ltd named herein, including the promotion by the Company of Elixinol Global Ltd in any Content on the Site, the Company...


CO2 GRO sees 20% higher pepper yields though 10 weeks of Hidroexpo Feasibility

CO2 GRO (CVE: GROW- OTCQB: BLONF) Vice President of Sales and Strategic Alliances Aaron Archibald joined Steve Darling from Proactive to bring details the company has seen very good results from their CO2 Delivery Solution commercial feasibility on greenhouse-grown peppers with Hidroexpo in...

1 day, 23 hours ago

2 min read